--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm ...
Tagrisso is currently under review with regulatory authorities in other countries around the world for this indication. Each year, an estimated 2.4 million people are diagnosed with lungcancer ...
Results that may be inaccessible to you are currently showing.